Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ADAG
- Price
- 2.03
- Stock movement up
- +0.34 (20.12%)
- Company name
- Adagene Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 95.68M
- Ent value
- 61.45M
- Price/Sales
- 927.06
- Price/Book
- 2.52
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 10.91%
- 1 year return (CAGR)
- 14.56%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADAG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 927.06 |
| Price to Book | 2.52 |
| EV to Sales | 595.45 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 47.13M |
| EPS (TTM) | -1.47 |
| FCF per share (TTM) | -1.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 103.20K |
| Gross profit (TTM) | -1.12M |
| Operating income (TTM) | -60.84M |
| Net income (TTM) | -55.44M |
| EPS (TTM) | -1.47 |
| EPS (1y forward) | -0.72 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1088.49% |
| Operating margin (TTM) | -58950.51% |
| Profit margin (TTM) | -53719.18% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 62.83M |
| Net receivables | 2.45K |
| Total current assets | 65.36M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 8.67M |
| Total assets | 66.52M |
| Accounts payable | 3.63M |
| Short/Current long term debt | 6.85M |
| Total current liabilities | 28.52M |
| Total liabilities | 28.61M |
| Shareholder's equity | 37.91M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -47.54M |
| Capital expenditures (TTM) | 42.35K |
| Free cash flow (TTM) | -47.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -146.23% |
| Return on Assets | -83.35% |
| Return on Invested Capital | -124.10% |
| Cash Return on Invested Capital | -106.52% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.69 |
| Daily high | 2.05 |
| Daily low | 1.69 |
| Daily Volume | 600K |
| All-time high | 29.60 |
| 1y analyst estimate | 9.51 |
| Beta | 0.73 |
| EPS (TTM) | -1.47 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| ADAG | S&P500 | |
| Current price drop from All-time high | -93.14% | -0.89% |
| Highest price drop | -95.30% | -19.00% |
| Date of highest drop | 24 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -93.38% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
95.68M
Marketcap category
Small-cap
Description
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Employees
138
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page